Performance of AstraZeneca’s Growth Platforms in 2Q16



AstraZeneca’s growth platforms

AstraZeneca (AZN) has classified a few products and regions as part of its growth platforms. Its growth platforms include respiratory and diabetes products Brilinta/Brilique and regional sales from emerging markets and Japan. The company has also added a new oncology franchise to its growth platforms for the first time due to new oncology products Tagrisso and Lynparza.

As we already saw, growth platforms contributed nearly 67% of AstraZeneca’s total revenues in 2Q16. In order to avoid duplication on a product and a regional basis, total product sales are adjusted for growth platforms in this part of the series.

Article continues below advertisement

Performance of growth platforms

Below are the performances of each of AstraZeneca’s growth platforms for 2Q16:

  • Respiratory product sales increased by 1% at constant exchange rates during 2Q16. This includes blockbuster drugs Symbicort and Pulmicort and new products Tudorza, Daliresp, and Duaklir. We’ll look at these in further detail in the other parts of this series.
  • Brilinta/Brilique, classified under AstraZeneca’s cardiovascular and metabolic disease (or CVMD) segment, is used to prevent blood clots in the heart and blood vessels. Brilinta/Brilique revenues increased by 51% at constant exchange rates during 2Q16.
  • The diabetes franchise includes Onglyza, Bydureon, Byetta, and Farxiga. This franchise reported a 13% growth in 2Q16 at constant exchange rates. Since this franchise is classified under the CVMD segment, we’ll look at details about these key products in later parts of the series.
  • Emerging markets and China have continued to grow year-over-year since 2014. Strong growth in emerging markets, including China, Brazil, and Russia, is mainly driven by established products. Emerging markets reported a 9% increase at constant exchange rates in 2Q16 and are expected to have mid-to-high-single-digit growth for 2016.
  • Revenues from Japan increased by 1% at constant exchange rates, mainly due to an increase in Crestor, Tagrisso, and other products.
  • As we’ve already seen, new oncology products, including Tagrisso for the treatment of lung cancer and Lynparza for the treatment of ovarian cancer, are classified as growth platforms. Tagrisso reported sales of $143 million in 2Q16. Lynparza is now available in 29 countries and reported sales of $98 million in 2Q16.

To divest risk, you can consider ETFs such as the Vanguard FTSE All-World Ex-US ETF (VEU), which holds ~0.5% of its total assets in AstraZeneca, 1.2% in Novartis (NVS), 0.6% in Novo Nordisk (NVO), and 0.3% in Teva Pharmaceutical (TEVA).


More From Market Realist